Results 101 to 110 of about 16,360 (195)
Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial
, 2017 Objective To characterise patients with active SLE based on pretreatment gene expression-defined peripheral immune cell patterns and identify clusters enriched for potential responders to abatacept treatment.Somnath Bandyopadhyay, Merri, Joan T, Bandyopadhyay, Somnath, Townsend, Robert M, Michael A Maldonado, Joan T Merrill, Omar Jabado, Robert M Townsend, Kelly, Sheila, Maldonado, Michael A, Nash, Peter, Connolly, Sean E, Sean E Connolly, Jabado, Omar, Westhovens, Rene, June Ye, Ye, June, Rene Westhovens, Peter Nash, Sheila Kelly +19 morecore +1 more sourceA critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations
Biologics: Targets & Therapy, 2014 Alvin F Wells,1,2 Nicole Jodat,1 Michael Schiff3 1Rheumatology and Immunotherapy Center, Franklin, WI, USA; 2Duke University Medical Center, Durham, NC, USA; 3University of Colorado, School of Medicine, Denver, CO, USA Abstract: There are now more ...Wells AF, Jodat N, Schiff Mdoaj Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial
, 2020 Background: Abatacept was well tolerated by patients with early diffuse cutaneous systemic sclerosis in a phase 2, double-blind randomised trial, with potential efficacy at 12 months. We report here the results of an open-label extension for 6 months. /
Singer, O, Gordon, JK, Frech, TM, Nagaraja, V, Denton, CP, Mayes, MD, Steen, VD, Spino, C, Bernstein, EJ, Domsic, RT, Molitor, JA, Sandorfi, N, Kafaja, S, Young, A, Castelino, FV, Chatterjee, S, Hsu, V, Khanna, D, Johnson, SR, Furst, DE, Hant, FN, Ajam, A, Whitfield, ML, McLain, R, Simms, RW, Fox, DA, Lafyatis, R, Chung, L, Distler, O, Matucci-Cerinic, M, Pope, JE, Allanore, Y +31 morecore Abatacept as treatment for monogenetic and refractory inflammatory disease
Abatacept is a potent anti-inflammatory drug. Its effectiveness and safety in the treatment of rheumatoid arthritis, psoriatic arthritis, and juvenile idiopathic arthritis has been well researched in randomized controlled trials.Berghuis, D., Dalm, Virgil A.S.H., van Hagen, P. Martin, Vermont, C.L., Legger, GE, Leavis, Helen, de Bree, G.J., van den Berg, J.M., Scholvinck, E.H., Henriet, Stefanie S V, Jansen, Marc, Mulders-Manders, K., Rutgers, Abraham, Buddingh, Emilie P., Hamann, Dörte, van de Veerdonk, Frank L., van Well, G.T.J., van Montfrans, Joris, Potjewijd, Judith, Hoppenreijs, E.P.A.H., Kuijpers, T.W., Bulatovic-Calasan, Maja, Zorg en O&O, CTI Research, Child Health, Infection & Immunity, Immuno/reuma patientenzorg, Centraal Diagnostisch Laboratorium, MS Reumatologie/Immunologie/Infectie +28 morecore Characterization of a novel homozygous CTLA4 variant. [PDF]
J Hum ImmunMcTaggart T, Lim JX, Akchengel A, Smith K, Landell-Wright S, Worth A, Fiaccadori V, Proctor I, Amarnath S, Carpenter B, Laurence A. +10 moreeuropepmc +1 more sourceSafety and effectiveness of abatacept in juvenile idiopathic arthritis: Results from the PRINTO/PRCSG registry
Objective: The aim of this study was to report the interim 5-year safety and effectiveness of abatacept in patients with JIA in the PRINTO/PRCSG registry.Griffin T., Udaondo C., Brueck D., Johnson N., Gitelman M. K., Stanevica V., Chalom B., Sukumarain S., Brown D., Parkinson E., Kingsbury D., Tzaribachev N., Morris P., Helling-Bakki A., Boulva S. F., Newhall L., Taylor J., Ballinger S., Guzman M., Rosenkranz M., Roth-Wojcicki E., Leblance C., Ardalan K., Tesher M., Nikishina I., Gillispie-Taylor M., Shaham B., Gastanaga M. E. P., Alperin R., Pepmueller P., Huber A., Zeft A., Oliveira-Ramos F., Curran M., Vehe R., Montin D., Brodus E., Lasky A., Hui-Yen J., Goldsmith D., Martini A., Lovell D., Miller M., Brochard K., Luca N., Huggins J., Panupattanapong S., Stern S., Del Rio A. Q., Onel K., Hazel E., Bohnsack J. F., Boneparth A., Robinson A., Bohnsack J., Koskova E., Spence S., Tucker L., Moorthy N., Chedeville G., Schulert G., Horwitz M., Ting T., Reiff A., Ramsey S., Walters H., Correll C., Mian Z., Rennebohm R., Ally M., Fernandes T., Zelf A., Lang B., Williams C., Rodriguez M., Terreri M. T., Tuttle P., Whitaker C., Versbsy J., Breedt J., Brunner H., Nolan B., Del-Castillo P. M. -., Durkee D., Peroni D., Rodriguez-Smith J., Hufnagel M., Dewitt E. M., Trachana M., Oliver M., Simon T. A., Jerath R., Olson J., Tarvin S., Levy D., Foeldvari I., Hobday P., Justice M., Grebenkina L., Davis A., Ruperto N., Mehta J., Appenzeller S., Quintero A., Dare J., Cassidy E., Suwairi W. M. S., Dalrymple A., Steigerwald K., Vehe R. K., Dominique A., Co D., Sharma N., Oliveira S., Compillo S., Herlin T., Cabral D., Huber A. M., Kelly L., Quartier P., Schmeling H., Treemarcki E., Kietz D., Wagner-Weiner L., Vora S., James K., Brunner J., Moreno E., Syed R., Minden K., Zulian F., Houghton K., Silverman E., Hiskey M., Binstadt B., Brunner H. I., Lvovich S., Griffin T. A., Spalding S., De Ranieri D., Simonini G., Go E., Chasnyk V., Torok K., Cartwright V., Marzan K., Orban I., Lovell D. J., Anton J., Wulffraat N., Henrickson M., Feller L., Costanzo D., Morishita K., Dhalla M., Grom A., O'Neil K., Hersh A., Patel J., Ramanan A., Hashkes P. P., Graham T., Penades I. C., Lazar C., Sarychev A., Waugaman B., Olivieri A. N., Horneff G., Louw I., Klausmeier T., Miraval T., Kamphuis S., Carrasco R., Stevens B., Gottlieb B., Guzman J., Cornejo G. V., Alexeeva E., Nocton J., Barhula S., Woodward A., Moore T., Stanevicha V., Blakley M., Inman C., Gotte A., Edens C., Toib D., Stringer E., Succimarri R. +189 morecore +1 more source